Novo Nordisk A/S Sponsored ADR (NVO)
Novo Nordisk to offer lower-priced versions of Wegovy for cash-paying customers
Novo Nordisk said on Wednesday it would offer lower-priced doses of its weight loss drug Wegovy at a reduced cost of $499 per month for cash-paying customers.
Down 39%. Is Novo Nordisk Stock a Buy on the Dip?
Novo Nordisk (NVO -2.09%) shareholders know all about the ups and downs of pharmaceutical stock investing. From the beginning of the coronavirus pandemic through the middle of last June, shares of NovoNordisk delivered more than a five-fold return.
Wall Street Analysts See Novo Nordisk (NVO) as a Buy: Should You Invest?
The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analysts changing their ratings often affect a stock's price.
Is Trending Stock Novo Nordisk A/S (NVO) a Buy Now?
Recently, Zacks.com users have been paying close attention to Novo Nordisk (NVO). This makes it worthwhile to examine what the stock has in store.
Prediction: Novo Nordisk Will Soar Over the Next 5 Years. Here's 1 Reason Why.
After quite a crushing bull stampede in 2024, the stock price of weight loss drug star Novo Nordisk (NVO -1.54%) has come down considerably. But I think that not only will the Wegovy maker recover, it'll zoom much higher in the coming years.
Novo Nordisk should withstand competition from new Eli Lilly diabetes drug, says Wall Street bank
JP Morgan is optimistic about Novo Nordisk (NYSE:NVO) despite competition from Eli Lilly's new drug, orforglipron. Its analysts reckon Novo will hold its ground if Lilly's upcoming trial results match Novo's existing treatments.
Prediction: These Could Be the Best-Performing Value Stocks Through 2030
Buying quality stocks when they're unpopular can be very rewarding.
Why Novo Nordisk Stock Popped on Friday
Novo Nordisk (NVO 5.03%) stock ran up 3.5% through 10:05 a.m. ET Friday morning on some good news for it (and for Eli Lilly) that's also probably bad news for Hims & Hers Health (HIMS -18.26%).
Shortage of Novo Nordisk's Wegovy and Ozempic drugs is resolved, FDA says
The long-running U.S. shortage of Novo Nordisk's blockbuster weight loss injection Wegovy and diabetes treatment Ozempic is resolved after more than two years, the Food and Drug Administration said. The FDA's decision will threaten the ability of compounding pharmacies to make far cheaper, unbranded versions of the injections over the next few months.
Novo Nordisk A/S (NVO) is Attracting Investor Attention: Here is What You Should Know
Zacks.com users have recently been watching Novo Nordisk (NVO) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Why Novo Nordisk Is A Strong Buy Despite Market Concerns
Novo Nordisk is doing exceptionally well in the face of the challenges posed by Eli Lilly. So, sales of Ozempic and Wegovy amounted to DKK 53.7 billion in the fourth quarter of 2024, increasing by 35.4% year-on-year despite competition from Mounjaro. In addition, at the end of January 2025, Novo Nordisk published data from a phase 1b/2a clinical study with amycretin, which beat even my wildest expectations.
Novo Nordisk alleges fraud after $1.3 billion deal to buy hypertension drug from KBP Biosciences
Novo Nordisk is seeking up to $830 million in damages from KBP Biosciences, according to a ruling by a Singapore court, as the Danish drugmaker says it was misled when it bought a new hypertension drug from KBP in 2023.
